Syndrome hémorragique sous cobimétinib : vigilance avec les nouveaux anticoagulants

Guern, A. Le; Lebas, D.; Thillard, Eve Marie; Martincic, C.; Wiart, T.; Modiano, P.

doi:10.1016/j.annder.2016.09.681

Cited by 2 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To the best of our knowledge, PK studies or case reports exploring clinical relevance of these DDIs between DOACs and anticancer agents are available only for dabigatran with erlotinib [ 27 ], bosutinib [ 28 ], ibrutinib [ 29 – 31 ], and crizotinib [ 32 ] and for apixaban with ibrutinib [ 33 , 34 ], cobimetinib [ 35 ], and cabozantinib [ 36 ]. To address the discrepancy between theoretical pharmacological basis and actual clinical impact, there is urgent need to exploit big data such as pharmacovigilance and healthcare databases in identifying and prioritizing relevant DDIs.…”

Section: Drug-drug Interactions Between Targeted Anticancer Agents Anmentioning

confidence: 99%

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia

Gatti

Raschi

Poluzzi

et al. 2020

Curr Heart Fail Rep

View full text Add to dashboard Cite

Purpose of Review Cardiotoxicity by anticancer agents has emerged as a multifaceted issue and is expected to affect both mortality and morbidity. This review summarizes clinical challenges in the management of oncological patients requiring anticoagulants for atrial fibrillation (AF) also considering the current outbreak of the COVID-19 (coronavirus disease 2019) pandemic, since this infection can add challenges to the management of both conditions. Specifically, the aims are manyfold: (1) describe the evolving use of direct oral anticoagulants (DOACs) in AF patients with cancer; (2) critically appraise the risk of clinically important drug-drug interactions (DDIs) between DOACs and oral targeted anticancer agents; (3) address expected DDIs between DOACs and candidate anti-COVID drugs, with implications on management of the underlying thrombotic risk; and (4) characterize the proarrhythmic liability in cardio-oncology in the setting of COVID-19, focusing on QT prolongation. Recent Findings AF in cardio-oncology poses diagnostic and management challenges, also due to the number of anticancer drugs recently associated with AF onset/worsening. Oral targeted drugs can potentially interact with DOACs, with increased bleeding risk mainly due to pharmacokinetic DDIs. Moreover, the vast majority of oral anticancer agents cause QT prolongation with direct and indirect mechanisms, potentially resulting in the occurrence of torsade de pointes, especially in susceptible patients with COVID-19 receiving additional drugs with QT liability. Summary Oncologists and cardiologists must be aware of the increased bleeding risk and arrhythmic susceptibility of patients with AF and cancer due to DDIs. High-risk individuals with COVID-19 should be prioritized to target preventive strategies, including optimal antithrombotic management, medication review, and stringent monitoring.

show abstract

Section: Drug-drug Interactions Between Targeted Anticancer Agents Anmentioning

confidence: 99%

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia

Gatti

Raschi

Poluzzi

et al. 2020

Curr Heart Fail Rep

View full text Add to dashboard Cite

show abstract

Apixaban/cobimetinib/vemurafenib

2019

Reactions Weekly

View full text Add to dashboard Cite

Syndrome hémorragique sous cobimétinib : vigilance avec les nouveaux anticoagulants

Cited by 2 publications

References 3 publications

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia

The Complex Management of Atrial Fibrillation and Cancer in the COVID-19 Era: Drug Interactions, Thromboembolic Risk, and Proarrhythmia

Apixaban/cobimetinib/vemurafenib

Contact Info

Product

Resources

About